Endeavor BioMedicines

Endeavor Biomedicines is a clinical-stage biotechnology company focused on developing transformational medicines with the potential to bring hope to patients suffering from life-threatening diseases. The company's lead candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway designed for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Additionally, Endeavor is developing ENV-501, an antibody-drug conjugate (ADC) targeting HER3-positive solid tumors. Founded in 2018, Endeavor Biomedicines operates in the Biotechnology and Health Care industries, with its headquarters located in the United States. Notably, the company recently secured a $132.50M Series C investment on 24 April 2024, with participation from a consortium of esteemed investors including Longitude Capital, Invus, T. Rowe Price, Ally Bridge Group, AyurMaya, Fidelity, Omega Funds, Velosity Capital, Tekla Capital Management, and Piper Heartland Healthcare Capital. Endeavor Biomedicines' commitment to addressing unmet medical needs and the strong support garnered from investors makes it a promising player in the biotech landscape.